Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Exploratory Evaluation of Technetium Tc 99m Tilmanocept by Intravenous (IV) Injection in Subjects With Liver Metastases From Colorectal Carcinoma Patients Using SPECT/CT Imaging Compared to Fluorodeoxyglucose (FDG) PET/CT Imaging

Next Previous
X
Search
Trial Profile

An Exploratory Evaluation of Technetium Tc 99m Tilmanocept by Intravenous (IV) Injection in Subjects With Liver Metastases From Colorectal Carcinoma Patients Using SPECT/CT Imaging Compared to Fluorodeoxyglucose (FDG) PET/CT Imaging

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 19 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tc 99m tilmanocept (Primary) ; Tc 99m tilmanocept (Primary)
  • Indications Adenocarcinoma; Colorectal cancer; Liver metastases
  • Focus Diagnostic use
  • Sponsors Navidea Biopharmaceuticals

    • Most Recent Events

    • 28 Oct 2019 Status changed from completed to discontinued.
    • 19 Mar 2019 Status changed from active, no longer recruiting to completed.
    • 04 Oct 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Dec 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top